Mivelsiran for Early Alzheimer's in Down Syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new drug called mivelsiran designed to slow early-stage Alzheimer's disease in adults with Down syndrome. The drug works by targeting amyloid, a protein that builds up in the brain and causes cognitive decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Down syndrome caused by trisomy 21 (three copies of chromosome 21)
- A PET scan shows amyloid buildup in your brain
- Your thinking and memory have been stable recently, not getting worse
- If you have seizures, they must be well-controlled with no seizures in the past 6 months
- Your liver and kidney function must be in acceptable range based on blood tests
- You have not received other experimental drugs recently or prior amyloid-targeting antibodies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
This trial is testing whether a form of vitamin B3 (called NAD) can help prevent or slow down Alzheimer's disease in people with Down syndrome. The goal is to see if this supplement can protect brain cells and improve memory or thinking.
This study tests whether a drug called memantine can help people with Down syndrome. It aims to see if it's safe and if it improves memory or thinking.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
Hear when a new Down Syndrome-Associated Alzheimer's Disease (DS-AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.